Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2002

View Archived Issues

Propecia significantly reduces hair loss, restores hair growth in men with androgenic alopecia

Bivalirudin reduces both thrombotic and bleeding complications in acute coronary syndromes

Pharmacological and pharmacokinetic profile of a new NK3 receptor antagonist

Peripheral COMT inhibitor with optimal properties designed at BIAL

First metabolic drug targets screened in Bayer/CuraGen alliance

Regeneron Q4 and year-end 2001 report

Quintiles and Kos sign commercialization agreement for Advicor and Niaspan

Cyproheptadine as effective as propranolol for neuroleptic-induced akathisia

Approvable letter received for use of Altocor in hypercholesterolemia

Amgen's Neulasta approved for febrile neutropenia

Guilford seeks expansion of indications for Gliadel in Europe

Zometa receives positive opinion for treatment of cancer-related bone metastases

SIGA Technologies' vaccine delivery system completes two clinical trials

Hybrigenics and Mindsense collaborate on biomarkers and drug targets for depression

Infectious disease research collaboration expanded by Cetek and Cubist

Heterocycles under study at Pfizer as inhibitors of 15-lipoxygenase

AHP describes preparation of novel soluble pegylated rapamycin derivatives

Preclinical milestone reached for Crucell human anti-CD46 antibody

Cyclic peptides synthesized for treatment of staphylococcal infections

Chronic inflammation, bone damage attenuated by M-40403 in rat model of arthritis

Factor Xa-inhibitory lactams disclosed by Bristol-Myers Squibb

New compounds identified at City of Hope to inhibit the glycation of proteins

Inhibitors of factor Xa described in patent by Cor Therapeutics

Researchers at Oncopeptides identify melphalan-containing peptides with antitumor activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...